The Europe Allergy Immunotherapy Market should witness market growth of 7.2% CAGR during the forecast period (2023-2030).
Allergy immunotherapy involves frequent injections that increase the amount to help the patient develop resistance. The patient's immune system becomes less vulnerable as the dosage gradually increases because more blocking antibodies are produced to fight the foreign chemicals that trigger allergies. Because allergic reactions often bring it on and are strongly related to other allergic disorders, asthma is a significant allergy component. As a result, the market is a subsegment of the overall market that is devoted to developing drugs for treating asthma and allergic disorders.
A major trend in the market is a shift toward more individualized and targeted treatment. Growing knowledge exists on the molecular processes that underlie allergic reactions. To satisfy each patient's unique needs, researchers and physicians are creating increasingly sophisticated, customized therapy. The development of biomarkers and diagnostic tools to assist in determining the underlying causes of allergies and directing treatment choices is also driven by this trend.
Most people who live in cities in Europe perform this in areas where the EU's regulations for air quality protection of human health are commonly surpassed. The UK government estimates that 1 to 2% of adults and 5 to 8% of youths in the country suffer from food allergies. Hypersensitivity to food cannot be cured. It necessitates ongoing management. A single action cannot make a consumer's risk disappear. Food allergies will increase because of these factors. Overall, the market is anticipated to expand in this region due to the rise in various allergens.
The Germany market dominated the Europe Allergy Immunotherapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $238.5 million by 2030. The UK market is estimated to grow at a CAGR of 6.2% during (2023-2030). Additionally, The France market should witness a CAGR of 8% during (2023-2030).
Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy. Based on Treatment Type, the market is segmented into Subcutaneous Immunotherapy (SCIT), and Sublingual Immunotherapy (SLIT) (Tablets, and Drops). Based on Allergy Type, the market is segmented into Allergic Rhinitis, Allergic Asthma, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc. (Mylan N.V.), Merck KGaA , NIOX Group plc , DMS Imaging SA, Adamis Pharmaceuticals Corporation, Stallergenes Greer International AG (B-Flexion), Allergy Therapeutics plc , DBV Technologies S.A., HAL Allergy B.V. (Droege International Group AG.), LETI Pharma, S.L.U.
Allergy immunotherapy involves frequent injections that increase the amount to help the patient develop resistance. The patient's immune system becomes less vulnerable as the dosage gradually increases because more blocking antibodies are produced to fight the foreign chemicals that trigger allergies. Because allergic reactions often bring it on and are strongly related to other allergic disorders, asthma is a significant allergy component. As a result, the market is a subsegment of the overall market that is devoted to developing drugs for treating asthma and allergic disorders.
A major trend in the market is a shift toward more individualized and targeted treatment. Growing knowledge exists on the molecular processes that underlie allergic reactions. To satisfy each patient's unique needs, researchers and physicians are creating increasingly sophisticated, customized therapy. The development of biomarkers and diagnostic tools to assist in determining the underlying causes of allergies and directing treatment choices is also driven by this trend.
Most people who live in cities in Europe perform this in areas where the EU's regulations for air quality protection of human health are commonly surpassed. The UK government estimates that 1 to 2% of adults and 5 to 8% of youths in the country suffer from food allergies. Hypersensitivity to food cannot be cured. It necessitates ongoing management. A single action cannot make a consumer's risk disappear. Food allergies will increase because of these factors. Overall, the market is anticipated to expand in this region due to the rise in various allergens.
The Germany market dominated the Europe Allergy Immunotherapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $238.5 million by 2030. The UK market is estimated to grow at a CAGR of 6.2% during (2023-2030). Additionally, The France market should witness a CAGR of 8% during (2023-2030).
Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy. Based on Treatment Type, the market is segmented into Subcutaneous Immunotherapy (SCIT), and Sublingual Immunotherapy (SLIT) (Tablets, and Drops). Based on Allergy Type, the market is segmented into Allergic Rhinitis, Allergic Asthma, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc. (Mylan N.V.), Merck KGaA , NIOX Group plc , DMS Imaging SA, Adamis Pharmaceuticals Corporation, Stallergenes Greer International AG (B-Flexion), Allergy Therapeutics plc , DBV Technologies S.A., HAL Allergy B.V. (Droege International Group AG.), LETI Pharma, S.L.U.
Scope of the Study
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
By Treatment Type
- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy (SLIT)
- Tablets
- Drops
By Allergy Type
- Allergic Rhinitis
- Allergic Asthma
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Viatris, Inc. (Mylan N.V.)
- Merck KGaA
- NIOX Group plc
- DMS Imaging SA
- Adamis Pharmaceuticals Corporation
- Stallergenes Greer International AG (B-Flexion)
- Allergy Therapeutics plc
- DBV Technologies S.A.
- HAL Allergy B.V. (Droege International Group AG.)
- LETI Pharma, S.L.U.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market At a Glance
Chapter 3. Market Overview
Chapter 4. Europe Allergy Immunotherapy Market by Distribution Channel
Chapter 5. Europe Allergy Immunotherapy Market by Treatment Type
Chapter 6. Europe Allergy Immunotherapy Market by Allergy Type
Chapter 7. Europe Allergy Immunotherapy Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Viatris, Inc. (Mylan N.V.)
- Merck KGaA
- NIOX Group plc
- DMS Imaging SA
- Adamis Pharmaceuticals Corporation
- Stallergenes Greer International AG (B-Flexion)
- Allergy Therapeutics plc
- DBV Technologies S.A.
- HAL Allergy B.V. (Droege International Group AG.)
- LETI Pharma, S.L.U.
Methodology
LOADING...
